Professor of Medicine
Dr. Kerry Savage
Dr. Daniel Renouf
Associate Professor of Medicine
Dr. Karen Gelmon
Professor of Medicine
Dr. Karamjit (Jiti) Gill
BSc, MD FRCPC
Clinical Assistant Professor of Medicine
BC Cancer – Vancouver
Dr. Jiti Gill is a medical oncologist at BC Cancer with a clinical practice specializing in gastrointestinal malignancies. She completed her medical degree and internal medicine training at Western University, followed by a hematology residency at McMaster University and a medical oncology residency at University of British Columbia.
Dr. Sharlene Gill
BSc, MD FRCPC, MPH, MBA
Professor of Medicine
BC Cancer – Vancouver
Medical Oncologist, Vancouver Cancer Centre
Professor, Faculty of Medicine, University of British Columbia
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in GI malignancies at BC Cancer – Vancouver. She received a BSc Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA). In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 120 peer-reviewed publications and book chapters to her credit. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee, Chair of the UBC Department of Medicine Mentoring Committee and Chair of the BC Cancer Medical Advisory Committee. She is the President of the Canadian Association of Medical Oncologists (2022-2024). Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.
Dr. Alina S Gerrie
MD FRCPC, MPH
Assistant Professor of Medicine
BC Cancer – Vancouver
Hematologist, Centre for Lymphoid Cancer, BC Cancer
Dr. Alina Gerrie is a hematologist and Assistant Professor in the Divisions of Medical Oncology and Hematology at the University of British Columbia (UBC) and a Clinician Investigator at the Centre for Lymphoid Cancer at BC Cancer, Vancouver Centre. She completed her medical degree and internal medicine residency at the University of Toronto, followed by hematology residency at UBC. She undertook a fellowship through the Royal College Clinical Investigator Program and earned a Master’s of Public Health degree from Harvard University, where her research included investigating the impact of genetic abnormalities on population-level outcomes in chronic lymphocytic leukemia (CLL) patients. Dr. Gerrie currently holds a Michael Smith Health Research Investigator Award and is involved in translational, clinical trial and outcomes-based research related to leukemia and lymphoma. Other academic interests include the investigation of novel therapeutics and cellular therapy for CLL and lymphoma.
Dr. Kim Nguyen Chi
MD FRCPC
Professor of Medicine
BC Cancer – Vancouver
Medical Oncologist, Vancouver Cancer Centre and Vancouver Prostate Centre
Chief Medical Officer, BC Cancer
Professor, Faculty of Health Sciences, Simon Fraser University
Shrum Chair in Prostate Cancer Research
Dr. Chi is a medical oncologist and the Chief Medical Officer of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia (BC), in Canada. He is also a Professor in the Faculty of Medicine at the University of British Columbia, a Professor in the Faculty of Health Sciences at Simon Fraser University, and the Shrum Chair in Prostate Cancer Research at BC Cancer.
Dr. Chi’s research in the field of genitourinary cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer. He also has been investigating circulating tumour DNA as a source of prognostic and predictive biomarkers for patients with metastatic prostate cancer. Dr. Chi is the past-Chair of the Genitourinary Disease and Investigational New Drugs Site Committees with the Canadian Cancer Trials Group, and has held peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defence, Movember, Prostate Cancer Foundation (USA), and Prostate Cancer Canada.
Dr. Chi is an author on over 280 articles in peer-reviewed journals including the Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, Cancer Discovery, Nature, and the New England Journal of Medicine.
Dr. Jonathan Loree
BMSc, MS, MD FRCPC
Associate Professor of Medicine
BC Cancer – Vancouver
CCTG Colon Cancer Disease Oriented Group Co-Chair
CCTG Senior Investigator
US NCI Colon Cancer Task Force Co-Chair
NANETs Guidelines Committee Co-Chair
COMMNETs Translational Research Group Co-Chair
Jonathan Loree is a medical oncologist at BC Cancer and Senior Investigator at CCTG with an interest in GI malignancies. He completed his medical oncology fellowship at BC Cancer and subsequently undertook a translational research fellowship at MD Anderson Cancer Center where he completed a Master’s of Science before returning to British Columbia. His research focus is translational research and biomarker development in colorectal cancer and neuroendocrine neoplasms.
Dr. Stephen K.L. Chia
MD FRCPC
Professor of Medicine
Head, Division of Medical Oncology, UBC Department of Medicine
BC Cancer – Vancouver
Medical Oncologist, BC Cancer
Head of Department of Clinical Research and Distinguished Scientist, BC Cancer and BC Cancer Research Institute
Chair British Columbia Breast Tumour Group
Dr. Chia is a Full Professor in the Division of Medical Oncology, Head of the Division of Medical Oncology, UBC and a staff medical oncologist with the BC Cancer, Vancouver Cancer Centre. He has a full-time clinical practice focusing on breast cancer and in new drug development. He is the Chair of the BC Cancer Breast Tumour Group and Head of the Department of Clinical Research. He is also the Co-Chair of the Breast Disease Site for Canadian Cancer Trials Group (CCTG).
Dr. Chia is recognized both nationally and internationally for his research work on breast cancer. His focus is on clinical trials and translational research. He has published over 180 peer-reviewed papers. His publications appear in international peer-reviewed journals including high-impact journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Cell, JAMA Oncology, and Nature and Nature Medicine. Dr. Chia has been a Subject Editor for British Journal of Cancer and The Oncologist, and is the current section author for UpToDate™ in the Prognostic/ Predictive Markers Section. He holds numerous peer reviewed grants.
Testing 6
Vestibulum dignissim vestibulum turpis non interdum. Morbi fermentum orci non tellus ullamcorper, non sagittis diam faucibus. Sed gravida.
Quisque faucibus, purus sit amet venenatis consequat, leo felis porttitor dui, a dictum mauris diam id est. Sed venenatis arcu imperdiet malesuada feugiat. Cras blandit et neque quis suscipit. Curabitur quis porta dolor, vitae mollis sapien. Cras feugiat, est ac ultrices consectetur, leo massa efficitur urna, a egestas augue lorem quis ligula. Fusce dapibus odio et pretium mattis. Vivamus convallis, lectus non imperdiet dapibus, magna felis congue orci, in suscipit diam lorem id nibh. Sed tempor suscipit lorem in porttitor. Donec dapibus vehicula ipsum quis condimentum. Nunc eros erat, eleifend vitae lobortis ut, accumsan non ex.
Cras nec tortor libero. Fusce risus diam, commodo in enim sit amet, porttitor vulputate enim. Fusce vestibulum aliquet dui, quis tempor augue lacinia nec. Nulla facilisi. Quisque tempor erat ac blandit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nam eleifend condimentum mi eget iaculis. Etiam sit amet lacus ac justo lacinia posuere a at velit.
Aenean nec egestas nisi. Cras ac tempus sem. Suspendisse interdum sem ut enim interdum, non tincidunt ex dictum. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nulla ullamcorper hendrerit massa, et varius tortor. Sed pretium arcu vitae suscipit pretium. Phasellus viverra ac mi nec molestie. Nulla suscipit mauris et efficitur lobortis. Etiam sollicitudin interdum ligula, sit amet consequat ante fermentum in. Ut eleifend pretium quam, ut sollicitudin justo consequat at. Pellentesque suscipit sollicitudin est, sit amet interdum augue efficitur non. Quisque vestibulum tincidunt velit ac rutrum. Nam vel pharetra dui, vitae iaculis nulla. Sed vitae nisi diam. Nulla euismod malesuada purus vitae vehicula. Sed turpis nunc, mattis venenatis mollis ut, lacinia sit amet orci.